The behavioural layer is the structured set of human-facing support, content, interactions, and design choices that wrap around a drug or device to help patients change their behaviour and sustain that change over time. It sits alongside the clinical pathway rather than inside it, and it is what makes the experience specific to each person, their progress, and their barriers.
GLP-1 care is the clearest example. The medicines produce substantial weight loss, and in real-world use more than half of patients discontinue within the first year. People stop early, before they see the full benefit, for a mix of reasons and many of them are behavioural: difficult side effects, unrealistic expectations, waning motivation, cost, and the everyday obstacles that make lasting change hard.
The evidence points the same way. A behaviour change programme that worked in person, delivered asynchronously through health coach-led messages in an app, was valued by patients and associated with sustained weight loss and psychological wellbeing at twelve months. That work was published in JMIR Formative Research. The lesson was not that the app was clever. It was that a well-designed behavioural layer produces outcomes the medication alone does not.
For teams building patient-facing products, this reframes where the hard part is. Not prescribing or fulfilment, difficult as those are, but the support that keeps someone engaged and safe through onboarding, plateaus, side effects, and the moments where life gets in the way.
Where this is explored in depth